Showing results (451-460 of 1,184) with videos related to
Sort By:
Pageof 119
Molecular Biology of the Cell|October 13, 2001
Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3'-end processing of pre-MRNAS Bléoo, X Sun, M J Hendzel, et al.Blood|April 15, 1995
Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneityC J Chapman, C I Mockridge, M Rowe, et al.Human Immunology|March 1, 1983
Selective reactivation of Epstein-Barr virus-specific cytotoxic T cells by stimulation in vitro with allogeneic virus-transformed HLA-homozygous typing cellsM Rowe, A B Rickinson, S R Beer, et al.Pediatric Diabetes|August 6, 2008
Insulin-related metabolism following hematopoietic stem cell transplantation in childhoodRonit Elhasid, Yael A Leshem, Myriam Weyl Ben Arush, et al.Fertility and Sterility|July 3, 2007
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphomaZeev Blumenfeld, Irith Avivi, Ari Eckman, et al.Journal of Virology|March 1, 1989
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteinsM Rowe, L S Young, K Cadwallader, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2017
Subclinical Herpes Simplex Virus Type 1 Infections Provide Site-Specific Resistance to an Unrelated PathogenAlexander M Rowe, Hongming Yun, Benjamin R Treat, et al.American Journal of Hematology|January 5, 2008
Non-Hodgkin's lymphoma presenting as an endobronchial tumor: report of eight cases and literature reviewAnna Solomonov, Tsila Zuckerman, Ludmila Goralnik, et al.Journal of Virology|January 9, 1999
Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2A G Eliopoulos, S M Blake, J E Floettmann, et al.Cancer Investigation|January 1, 1997
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?C L Bennett, R Golub, T M Waters, et al.Pageof 119